Michael J. Bury

The Identification and Pharmacological Characterization of 6-( <i>tert</i> -Butylsulfonyl)- <i>N</i> -(5-fluoro-1 <i>H</i> -indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase

Pamela A. Haile, Bartholomew J. Votta, Robert W. Marquis et al. · Journal of Medicinal Chemistry · 2016 · 122 citations · Full text

Discovery of GSK2193874: An Orally Active, Potent, and Selective Blocker of Transient Receptor Potential Vanilloid 4

Mui Cheung, Weike Bao, David J. Behm et al. · ACS Medicinal Chemistry Letters · 2017 · 94 citations · Full text

Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[<i>d</i>]thiazol-5-ylamino)-6-(<i>tert</i>-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases

Pamela A. Haile, Linda Casillas, Bartholomew J. Votta et al. · Journal of Medicinal Chemistry · 2019 · 65 citations · Full text

Chronic Inflammatory Diseases, Drug Target, Immunology +25

Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors

Krista Goodman, Michael J. Bury, Mui Cheung et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 52 citations · Full text

Pharmaceutical Science, Medicine, Drug Development +3

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel

Pamela A. Haile, Linda Casillas, Michael J. Bury et al. · ACS Medicinal Chemistry Letters · 2018 · 35 citations · Full text